Online and offline information seeking behaviours of people living with HIV in a clinic-based setting

2019 ◽  
Vol 68 (6/7) ◽  
pp. 517-533
Author(s):  
Edda Tandi Lwoga
Keyword(s):  
Human Immunodeficiency Virus ◽  
Information Seeking ◽  
Health Knowledge ◽  
Sub Saharan Africa ◽  
People Living With Hiv ◽  
Online Information ◽  
Content Type ◽  
Immunodeficiency Virus ◽  
Health Promoting ◽  
Sub Saharan

Purpose The purpose of this study sought to determine the characteristics that distinguish online from offline information seekers among people living with human immunodeficiency virus (PLHIV) in selected regional hospitals of Tanzania. Design/methodology/approach Questionnaire-based survey was conducted among 341 adults with human immunodeficiency virus (HIV) infection attending the HIV clinics in the regional referral hospitals in Mwanza, Mbeya and Dar es Salaam, Tanzania. The study used multivariate logistic regressions to determine factors that distinguish online HIV information seekers from offline HIV information seekers. Findings One in every five survey participants sought online HIV information (19.6 per cent, n = 67). Both higher level of education (odds ratio (OR) = 1.765, 95 per cent confidence interval (CI) = 1.208-2.58) and intention to use internet in future (OR = 1.566, 95 per cent CI 1.148-2.136) were predictors of online HIV information seeking behaviour at multivariate analysis. Respondents who sought online information reported to have gained knowledge such as; to understand their conditions better (77.4 per cent, n = 41) and understand information received from health care workers (66 per cent, n = 35), as well as acquisition of health promoting behaviour such as; asking questions during doctor’s visit (55 per cent, n = 35) and consulting a clinician when they have problems (64.3 per cent, n = 33). The offline HIV information seekers (n = 274) did not use internet due to lack of information seeking skills (44.3 per cent, n = 113) and lack of access to internet connectivity (30.2 per cent, n = 77). Originality/value This is a comprehensive study that differentiates online from offline HIV information seekers in the context of sub-Saharan Africa. The results suggest that interventions to improve online access information will empower patients and probably positively affect their health knowledge and health promoting behaviours.

scholarly journals Human immunodeficiency virus infection and inflammatory arthritis: A review of clinical and imaging features

2017 ◽  
Vol 21 (2) ◽  
Author(s):  
Farhana E. Suleman ◽  
Mahmood M.T.M. Ally
Keyword(s):  
Human Immunodeficiency Virus ◽  
Pain Syndrome ◽  
Sub Saharan Africa ◽  
People Living With Hiv ◽  
Imaging Features ◽  
The People ◽  
Immunodeficiency Virus ◽  
Sub Saharan ◽  
Living With Hiv ◽  
Articular Pain

The reported prevalence of articular manifestations of human immunodeficiency virus (HIV) varies, but with sub-Saharan Africa accounting for almost 70% of the people living with HIV, this results in a considerable burden of disease in the region. The spectrum of clinical presentation described, includes articular pain syndrome, HIV-associated arthropathy and seronegative spondyloarthropathies, among others. This brief review serves to create awareness of the clinical and imaging presentation of this spectrum of disease as there is significant morbidity associated with these conditions if treatment is delayed.

Human immunodeficiency virus funding and access to treatment in sub-Saharan Africa

2021 ◽  
pp. 095646242110422
Author(s):  
Reuben Granich ◽  
Somya Gupta ◽  
Brian Williams
Keyword(s):  
Human Immunodeficiency Virus ◽  
Viral Suppression ◽  
Hiv Treatment ◽  
Sub Saharan Africa ◽  
People Living With Hiv ◽  
Access To Treatment ◽  
Immunodeficiency Virus ◽  
Sub Saharan ◽  
Living With Hiv ◽  
Hiv Funding

Human immunodeficiency virus (HIV) treatment prevents illness, death, and transmission. The 90-90-90 disease control target is only 73% of people living with HIV virally suppressed. For 2010 to 2019, we abstracted HIV funding data for 40 countries in sub-Saharan Africa (70% of global HIV burden and >99% of HIV burden in the region in 2018). During 2010–2019, there was ∼$52 billion funding for 40 countries (99% Africa HIV burden). Domestic funding ranged from $0 to $3.2 billion. PEPFAR funding was $32 billion (average $1.4 billion; range $0.089–4.3 billion) among 22 countries. Global Fund averaged $306 million ($1.9 million to $1.1 billion) for 40 countries. Among PLHIV, known HIV status averaged 80% (11% to 94%). ART coverage averaged 64% (9% to 90%). Viral suppression among PLHIV ranged from 8% to 87%. Of the 40 countries, 21 reported under 60% of PLHIV to be on treatment and 13 did not report viral suppression for 2018. Achieving 90-90-90 is feasible in challenging settings if resources are used efficiently. Despite the significant investment in the HIV response, many countries have not reached the 90-90-90 target. Greater attention to efficiency and prioritizing important targets will be required to end AIDS in Africa.

scholarly journals A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans

2016 ◽  
Vol 3 (3) ◽  
Author(s):  
Sean E. Collins ◽  
Philip M. Grant ◽  
Francois Uwinkindi ◽  
Annie Talbot ◽  
Eric Seruyange ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Antiretroviral Therapy ◽  
Tenofovir Disoproxil Fumarate ◽  
Sub Saharan Africa ◽  
Current Therapy ◽  
Virologic Suppression ◽  
Open Label ◽  
Immunodeficiency Virus ◽  
Sub Saharan ◽  
Hiv 1

Abstract Background.  Many human immunodeficiency virus (HIV)-infected patients remain on nevirapine-based antiretroviral therapy (ART) despite safety and efficacy concerns. Switching to a rilpivirine-based regimen is an alternative, but there is little experience with rilpivirine in sub-Saharan Africa where induction of rilpivirine metabolism by nevirapine, HIV subtype, and dietary differences could potentially impact efficacy. Methods.  We conducted an open-label noninferiority study of virologically suppressed (HIV-1 ribonucleic acid [RNA] < 50 copies/mL) HIV-1-infected Rwandan adults taking nevirapine plus 2 nucleos(t)ide reverse-transcriptase inhibitors. One hundred fifty participants were randomized 2:1 to switch to coformulated rilpivirine-emtricitabine-tenofovir disoproxil fumarate (referenced as the Switch Arm) or continue current therapy. The primary efficacy endpoint was HIV-1 RNA < 200 copies/mL at week 24 assessed by the US Food and Drug Administration Snapshot algorithm with a noninferiority margin of 12%. Results.  Between April and September 2014, 184 patients were screened, and 150 patients were enrolled; 99 patients switched to rilpivirine-emtricitabine-tenofovir, and 51 patients continued their nevirapine-based ART. The mean age was 42 years and 43% of participants were women. At week 24, virologic suppression (HIV-1 RNA level <200 copies/mL) was maintained in 93% and 92% in the Switch Arm versus the continuation arm, respectively. The Switch Arm was noninferior to continued nevirapine-based ART (efficacy difference 0.8%; 95% confidence interval, −7.5% to +12.0%). Both regimens were generally safe and well tolerated, although 2 deaths, neither attributed to study medications, occurred in participants in the Switch Arm. Conclusions.  A switch from nevirapine-based ART to rilpivirine-emtricitabine-tenofovir disoproxil fumarate had similar virologic efficacy to continued nevirapine-based ART after 24 weeks with few adverse events.

Hepatitis B virus activity in untreated hepatitis B e antigen–negative human immunodeficiency virus–hepatitis B virus co-infected patients from sub-Saharan Africa

2019 ◽  
Vol 113 (8) ◽  
pp. 437-445
Author(s):  
Anders Boyd ◽  
Menan Gerard Kouamé ◽  
Laura Houghtaling ◽  
Raoul Moh ◽  
Delphine Gabillard ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Hbv Dna ◽  
Sub Saharan Africa ◽  
Hepatitis B E Antigen ◽  
Hiv Rna ◽  
B Virus ◽  
Immunodeficiency Virus ◽  
Sub Saharan

Abstract Background In human immunodeficiency virus (HIV) and hepatitis B virus (HBV) co-infected patients from sub-Saharan Africa with hepatitis B e antigen (HBeAg)-negative status, data are limited on the evolution of HBV activity when antiretroviral treatment (ART) is absent. Methods A total of 43 HBeAg-negative co-infected patients not indicated for ART (per concomitant World Health Organization recommendations) were followed during participation in a randomized controlled trial in Côte d’Ivoire. Chronic HBeAg-negative phases were classified at yearly visits and defined as ‘infection’ (HBV DNA ≤10 000 copies/mL and normal alanine aminotransferase [ALT]) or ‘hepatitis’ (HBV DNA >10 000 copies/mL and/or above normal ALT). Dispersion in HBV DNA and ALT levels during follow-up was assessed using interquartile range (IQR) regression. Results During a median 25 months (IQR 19–31), 17 (40%) patients consistently had ‘infection’, 5 (12%) consistently had ‘hepatitis’ and 21 (48%) fluctuated between phases. Wider dispersion in HBV DNA over time was associated with higher baseline HIV RNA (p=0.02) and higher baseline HBV DNA levels (p=0.008), while wider dispersion in ALT was associated with higher baseline HIV RNA (p<0.001), higher baseline ALT levels (p=0.02) and baseline hepatitis surface antigen >4.0 log10 IU/mL (p=0.02). Conclusions HBV activity is common with HBeAg-negative status, whose variation is partly linked to HIV replication. Fluctuations in disease phase make it difficult to assess the risk of morbidity and mortality after ART initiation.

scholarly journals Stroke in Human Immunodeficiency Virus-infected Individuals in Sub-Saharan Africa (SSA): A Systematic Review

2018 ◽  
Vol 27 (7) ◽  
pp. 1828-1836 ◽  
Author(s):  
Amir Abdallah ◽  
Jonathan L. Chang ◽  
Cumara B. O'Carroll ◽  
Abdu Musubire ◽  
Felicia C. Chow ◽  
...  
Keyword(s):  
Systematic Review ◽  
Human Immunodeficiency Virus ◽  
Sub Saharan Africa ◽  
Immunodeficiency Virus ◽  
Sub Saharan
Sign in / Sign up

Export Citation Format

Share Document